Institute of Translational Genomics at Helmholtz Munich

We generate insights from big biomedical data to improve human health.

At the Institute of Translational Genomics (ITG) we generate insights from big biomedical data to improve human health.

Our research leverages big data in genetics and genomics for medically important human traits. We aim to translate insights from genomics into mechanisms of disease development and progression, shortening the path to translation and empowering precision medicine.

Our overarching aims are to

Characterise the genetic architecture of common complex diseases of high public health burden;
Generate insights into the biological mechanisms underpinning chronic disease development and progression;
Develop robust methods for integrating big data to address key biomedical challenges;
Catalyse pathways to translation for disease prognosis, management and treatment.

Numerous genetic studies have identified many risk variants for type 2 diabetes (T2D) – but which genes and proteins are actually involved in the disease mechanisms? An international team led by Helmholtz Munich has now used globally collected…

Researchers have conducted the most comprehensive analysis to date linking plasma proteins to genetic variation in individuals from continental Africa. Their work addresses a long-standing gap by studying a population grossly underrepresented in…

The European Commission has appointed Prof. Eleftheria Zeggini, Director of the Institute of Translational Genomics at Helmholtz Munich, to the Scientific Council of the European Research Council (ERC). Alongside five newly selected members, she will…

Icon, Computational Health, Featured Publication

Researchers at Helmholtz Munich have found that the body begins signaling the risk of type 2 diabetes many years before the disease is diagnosed. In a long-term study, the team examined hundreds of blood metabolites – small molecules that reflect…

Helmholtz Munich is part of the EU research initiative PROBE, which aims to fundamentally transform the way osteoarthritis is diagnosed and treated. The project is funded through HORIZON EUROPE by the Innovative Health Initiative and has a total…

A recent study led by Prof. Eleftheria Zeggini, Director of the Institute of Translational Genomics at Helmholtz Munich, provides new insights into how genetic risk for type 2 diabetes (T2D) can influence a wide range of health conditions beyond…

We aim to empower precision medicine by translating insights from big biomedical data.

Visit the group's page

Genetic basis of human immune response variation

Visit the group's page

We aim to improve personalized healthcare by integrating OMICs data using statistical, bioinformatical and machine learning approaches.

Visit the group's page

The mission of our research group is to explore the molecular causes in children with very early onset inflammatory bowel disease (VEO-IBD), a life-threatening condition

Visit the group's page

Prof. Dr. Dr. Eleftheria Zeggini

Director of the Institute of Translational Genomics; Liesel Beckmann Distinguished Professor at Technical University Munich University Hospital; Metabolic and Computational Health (CONNECT) Programme Spokesperson

View profile

Dr. med. Sarah Kim-Hellmuth

Group Leader

View profile

Rui Wang-Sattler

Group Leader

View profile

Daniel Kotlarz

Group Leader

View profile

49

Employees

17

Nationalities

Bocher, O. ; Arruda, A.L. ; Yoshiji, S. ; Zhao, C. ; Huerta-Chagoya, A. ; Su, C.Y. ; Yin, X. ; Cammann, D. ; Taylor, H.J. ; Chen, J. ; Suzuki, K. ; Mandla, R. ; Yang, T.Y. ; Matsuda, F. ; Mercader, J.M. ; Flannick, J. ; Meigs, J.B. ; Wood, A.C. ; Vujkovic, M. ; Voight, B.F. ; Spracklen, C.N. ; Rotter, J.I. ; Morris, A.P. ; Zeggini, E.

Unravelling the molecular mechanisms causal to type 2 diabetes across global populations and disease-relevant tissues.

Emmanouil, C. ; Anezaki, M. ; Simistiras, A. ; Glentis, S. ; Scarmeas, N. ; Hatzis, P. ; Rouskas, K. ; Dimas, A.S.

Rapid remodeling of the human gut microbiome in response to short-term animal product restriction and associations with host molecular phenotypes.

Haghipanah, M. ; Rohani, P. ; Rohlfs, M. ; Shahrokh, S. ; Farahmand, F. ; Anvari, M.S. ; Witzel, M. ; Ahmadipour, S. ; Sohouli, M. ; Dehghani, S.M. ; Klein, C. ; Kotlarz, D.M. ; Soltani, B.M. ; Totonchi, M.

Clinical and genomic features of Iranian patients with very early onset IBD.

Harada, M. ; Adam, J. ; Han, S. ; Shi, M. ; Ge, J. ; Lintelmann, J. ; Cecil, A. ; Zukunft, S. ; Prehn, C. ; Witting, M. ; Scheerer, M.F. ; Neschen, S. ; Irmler, M. ; Beckers, J. ; Adamski, J. ; Teupser, D. ; Linkohr, B. ; Gieger, C. ; Hrabě de Angelis, M. ; Peters, A. ; Wang-Sattler, R.

Urea cycle modulation by combined SGLT2 inhibitors and metformin.

Kreitmaier, P. ; Stergiou, O. ; Katsoula, G. ; Tutino, M. ; Bittner, N. ; Shah, K.M. ; Swift, D. ; Wilkinson, J.M. ; Zeggini, E.

The epigenomic landscape of primary tissues in osteoarthritis.